Recently, the National Development and Reform Commission and the Ministry of Industry and Information Technology jointly issued the 2009 second batch of newly increased investment plans in central budget for revitalization and technology innovation of national key industries. The “high-technology industrialized project of annual production of 15 million dezocine injections” was shortlisted, and obtained a RMB 2.6 million investment subsidy capital from the central budget.
Dezocine injection is a new non-addictive strong analgesic jointly developed by Yangtze River Pharmaceutical Group Co., Ltd. and China Pharmaceutical University. This project is a domestic unique production variety developed independently. The construction period is two years and the total investment is RMB 72.05 million. Invention patent and packaging design patent will be applied for. After the construction, it is planned to reach the annually 15 million injections’ production capacity for dezocine injections.
It is learned that in order to confront the financial crisis, the state has promulgated the second batch of subsidy capital for revitalization of key industries and technology innovations to help the enterprises accelerate the projects’ implementation progress and achieve the expansion of investment and the efficiency. Taizhou has altogether 5 projects got shortlisted, and in total obtained RMB 25.8 million investment subsidy in the central budget.